Perseus Proteomics Inc. (TYO:4882)
Japan · Delayed Price · Currency is JPY 410.00
+1.00 (0.24%)
Aug 6, 2025, 3:30 PM JST
Regulus Therapeutics Revenue
In the fiscal year ending March 31, 2025, Perseus Proteomics had annual revenue of 120.00M JPY with 20.00% growth. Perseus Proteomics had revenue of 36.93M in the quarter ending March 31, 2025, with 27.34% growth.
Revenue
120.00M
Revenue Growth
+20.00%
P/S Ratio
50.39
Revenue / Employee
3.75M
Employees
32
Market Cap
6.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 120.00M | 20.00M | 20.00% |
| Mar 31, 2024 | 100.00M | 6.00M | 6.38% |
| Mar 31, 2023 | 94.00M | 23.00M | 32.39% |
| Mar 31, 2022 | 71.00M | 4.00M | 5.97% |
| Mar 31, 2021 | 67.00M | -18.00M | -21.18% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.22B |
| Daiichi Sankyo Company | 1,924.68B |
| Takeda Pharmaceutical Company | 4,480.25B |
| HOYA Corporation | 876.09B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,036.17B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |